On Oct. 25, 2023, Bavarian Nordic announced that the U.S. Centers for Disease Control and Preventionﾒs (CDC) Advisory Committee on Immunization Practices (ACIP) had voted in favor of recommending the routine use of JYNNEOSﾮ, the Companyﾒs FDA-approved mpox vaccine, in adults at risk of mpox infection. Specifically, the ACIP voted to recommend that individuals 18 years and older with certain risk factors should receive the two-dose regimen of JYNNEOS.

Previously, ACIP had recommended JYNNEOS for individuals at risk of mpox only during an outbreak.